Replies to post #140555 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Here's what Kayopharm said about the drug:

About KPT-350

KPT-350 is an IND-ready oral SINE compound with a preclinical data package supporting potential efficacy across a number of neurological and inflammatory conditions. XPO1 mediates the nuclear export of multiple proteins that impact neurological and inflammatory processes. Consequently, inhibition of XPO1 by KPT-350 results in a reduction in inflammation and neurotoxicity and an increase in neuroprotective responses. KPT-350 penetrates the blood brain barrier to a greater degree than other SINE compounds. With a research and development program led by Sharon Tamir, Director, Strategic Product Development and Head of Neurodegenerative and Infectious Diseases and Dr. Sharon Shacham, Founder, President and CSO, oral KPT-350 is supported by extensive preclinical data showing potential efficacy in animal models of amyotrophic lateral sclerosis, traumatic brain injury, and other neurological conditions.

http://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-agreement-biogen-acquire-kpt-350-treatment


Another link -

https://huntingtonsdiseasenews.com/2017/05/09/huntingtons-disease-disrupted-path-molecules-neurons/